PROTAC polypeptide targeting ZMYND8 protein and application thereof

Through the PROTAC polypeptide and nanoselenium delivery system targeting ZMYND8 protein, the problem of side effects and high recurrence rates of AML treatment is solved, effective inhibition of AML cells and prolong survival time, filling the targeted degradation drugs of ZMYND8 protein blank.

CN119019505AActive Publication Date: 2024-11-26XI AN JIAOTONG UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411129660.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-16
Publication Date
2024-11-26
Estimated Expiration
2044-08-16

AI Technical Summary

Technical Problem

The existing AML treatment methods have significant toxic side effects, high disease recurrence rate, poor tolerance in elderly patients, and lack targeted degradation drugs for ZMYND8 protein.

Method used

A PROTAC polypeptide targeting the ZMYND8 protein was developed to achieve its degradation by having high binding capacity with the ZMYND8 protein. The nanoselenium delivery system was used to bring the polypeptide into AML cells to inhibit cell proliferation and degrade ZMYND8 protein.

Benefits of technology

Effectively inhibit the proliferation of AML cells, reduce tumor burden, prolong the survival time of AML mice, and promote apoptosis in bone marrow samples of AML patients in vitro, providing a new AML treatment strategy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119019505A_ABST
    Figure CN119019505A_ABST
Patent Text Reader

Abstract

The invention provides a PROTAC polypeptide targeting ZMYND8 protein and application of the PROTAC polypeptide, and belongs to the technical field of polypeptide. The amino acid sequence of the PROTAC polypeptide is shown as SEQ ID NO.1, the PROTAC polypeptide and ZMYND8 protein have high binding capacity, proliferation of cells can be effectively inhibited when the PROTAC polypeptide is delivered into leukemia cells through a nano-selenium delivery system, and meanwhile the PROTAC polypeptide has the capacity of degrading the ZMYND8 protein in the cells in a targeted mode. The PROTAC polypeptide can be applied to preparation of drugs for preventing and / or treating hematological malignancies or preparation of reagents for degrading ZMYND8 protein. The PROTAC polypeptide drug targeting ZMYND8 can provide a new treatment strategy for targeted treatment of hematological malignancies.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of protein polypeptides, and specifically relates to a protein degradation targeting chimera (PROTAC) polypeptide targeting ZMYND8 protein and an application thereof. Background Art

[0002] Acute myeloid leukemia (AML) is one of the common hematological malignancies in humans, and its incidence is increasing year by year. In the treatment of AML, traditional chemotherapy and allogeneic hematopoietic stem cell transplantation are the main treatments. In particular, the advancement of hematopoietic stem cell transplantation technology has improved the survival rate of young, medium- and low-risk AML patients to a certain extent. However, the significant toxic side effects of chemotherapy, the high recurrence rate of the disease, and the poor tolerance of elderly patients to treatment are still the main obstacles to the long-term survival of AML patients. In view of this, the development of new AML treatment strategies with high targeting, better efficacy and lower side effects is of great significance to improving the quality of life and survival rate of AML patients.

[0003] ZMYND8 (zinc finger MYND-type containing 8) is a transcriptional regulatory protein. Its N-terminus contains a plant homeodomain (PHD), a bromodomain (BRD), and a Pro-Trp-Trp-Pro (PWWP) chromatin binding domain, and its C-terminus contains a MYND-type zinc finger domain for protein-protein interaction. The N-terminal PHD-BRD-PWWP domain of ZMYND8 recognizes several acetyl and methyl lysines on histones in vitro

[0004] residues. As a histone "reader", ZMYND8 can recognize various histone post-translational modifications and certain specific mutated histones, and participate in cell transcriptional regulation. Studies have shown that ZMYND8 may play a key role in the tumorigenesis of breast cancer, prostate cancer, colorectal cancer and cervical cancer. Cao et al. found that in AML cells, ZMYND8 binds to the leukemia-specific enhancer of MYC and (or) the enhancer of IRF8, which can regulate the expression of MYC and (or) IRF8, thereby maintaining the growth of AML cells. It was also found that ZMYND8 only regulates MYC and IRF8 in AML (if IRF8 is expressed), and this pathway does not exist in other solid tumors. It proves that ZMYND8 is an AML-dependent transcriptional regulator. Therefore, ZMYND8 can be used as a target for AML treatment. At present, there is no use of small molecule inhibitors or targeted degradation drugs for ZMYND8 protein at home and abroad. Summary of the invention

[0005] In view of this, the object of the present invention is to provide a PROTAC polypeptide targeting the ZMYND8 protein, which has a high binding ability with the ZMYND8 protein, effectively degrades the ZMYND8 protein, exerts an anti-cancer effect, and fills the gap in PROTAC drugs targeting the transcriptional regulatory protein ZMYND8.

[0006] In a first aspect, the present invention provides a PROTAC polypeptide targeting ZMYND8, wherein the amino acid sequence of the PROTAC polypeptide is shown in SEQ ID NO: 1.

[0007] Preferably, the binding constant of the PROTAC polypeptide to the ZMYND8 protein is 324 nM.

[0008] In a second aspect, the present invention provides use of the PROTAC polypeptide in the preparation of a drug for preventing and / or treating leukemia.

[0009] Preferably, the PROTAC polypeptide is used to prepare a drug for inhibiting the proliferation of acute myeloid leukemia cells.

[0010] Preferably, the acute myeloid leukemia cells are MOLM-13, THP-1, MV4-11, M07e, NB4 or primary cells from bone marrow samples of patients with acute myeloid leukemia.

[0011] In a third aspect, the present invention provides the use of the PROTAC polypeptide in the preparation of a reagent for degrading ZMYND8 protein.

[0012] In a fourth aspect, the present invention provides a drug comprising the PROTAC polypeptide and a pharmaceutically acceptable excipient or carrier.

[0013] The drug can be prepared into a pharmaceutically acceptable pharmaceutical preparation, such as an oral preparation or an injection preparation, after adding suitable excipients. Exemplarily, oral preparations include capsules, tablets, granules or other liquid preparations, such as mixtures, suspensions, syrups, aromatic waters, etc. Exemplarily, the excipients that can be added include stabilizers, suspending agents, pH regulators, flavoring agents, colorants, disintegrants, fillers, solubilizers, excipients, humectants, thickeners, wetting agents, penetrants, diluents, flocculants, etc.

[0014] Preferably, the carrier is a nano-delivery system.

[0015] Further preferably, the nano delivery system is nano-selenium, nano-gold or liposome.

[0016] More preferably, when the nano delivery system is nano selenium, the drug is prepared according to the following steps:

[0017] The polypeptide, the aqueous solution of selenium salt and the solution of chitosan are mixed and then placed in a water bath, and vitamin C is added and reacted to obtain the product.

[0018] Preferably, the molar mass ratio of the PROTAC polypeptide, selenium salt and vitamin C is 1:8-12:70-90.

[0019] Preferably, the mass concentration of the chitosan solution is 0.3-0.8%, and the dosage ratio of the chitosan solution to the polypeptide is 150 μL: 1 mg.

[0020] Preferably, after the PROTAC polypeptide, chitosan solution and selenium salt are mixed, they are mixed at 45-55°C, vitamin C is added, the reaction is continued for 15-25 minutes, stabilized at room temperature for more than 2 hours, and then stored at 4°C.

[0021] The present invention provides a PROTAC polypeptide targeting ZMYND8, and the amino acid sequence is shown in SEQ ID NO: 1. The present invention detects the binding ability of the PROTAC polypeptide to the ZMYND8 protein by isothermal calorimetric titration experiments, and the binding constant of the PROTAC polypeptide to the ZMYND8 protein is 324nM, indicating that the PROTAC polypeptide has a strong binding ability to the ZMYND8 protein. The PROTAC polypeptide is delivered to AML cells through a nano-selenium delivery system, which can effectively inhibit cell proliferation and target the degradation of the ZMYND8 protein of AML cells.

[0022] The PROTAC polypeptide provided by the present invention can effectively reduce tumor burden in an in vivo AML mouse model and prolong the survival time of AML mice.

[0023] The AML animal model was an NSG mouse model injected with MOLM-13-Luc via the tail vein.

[0024] The PROTAC polypeptide provided by the present invention can effectively promote AML cell apoptosis in primary cells of bone marrow samples of AML patients in vitro.

[0025] It can be seen that the PROTAC polypeptide can be used in the preparation of drugs for preventing and / or treating leukemia or in the preparation of reagents for degrading ZMYND8 protein.

[0026] The present invention provides a drug for preventing and / or treating leukemia, including a PROTAC polypeptide and a delivery system. The ZMYND8 PROTAC@NanoSe drug prepared using nano-selenium as a delivery system can provide a new treatment strategy for malignant blood diseases including myeloma, lymphoma, acute myeloid leukemia, etc., filling the gap in drugs for targeted degradation of polypeptides targeting ZMYND8 worldwide. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 The design results of the polypeptide for ZMYND8 provided by the present invention, wherein A is a schematic diagram of the crystal structure of the ZMYND8 homodimer; B and C are the results of protein-assisted design of the ZMYND8 polypeptide. D is the HPLC characterization result of the drug polypeptide. E and F are the affinity test results of the ZMYND8 PROTAC drug polypeptide with the ZMYND8 protein and the MDM2 protein, respectively.

[0028] Figure 2 Figure 5 is the test result of the in vitro proliferation inhibition activity of ZMYND8 PROTAC drug, where A is the test of the drug's ability to inhibit cancer cell proliferation; B is the result of protein immunoblotting to detect the degradation of ZMYND8 protein in cancer cells by the drug; C is the result of protein immunoblotting to detect the degradation of ZMYND8 protein by ZMYND8 PROTAC drug; D and E are statistical analyses of the immunoblot in Figure C.

[0029] Figure 3 The ZMYND8 PROTAC drug induced apoptosis of primary cells in AML patient bone marrow samples in vitro;

[0030] Figure 4 Animal experiments to test drug efficacy, where A is a schematic diagram of the establishment of the AML mouse model and drug administration. B is the effect of the control group, reverse peptide and ZMYND8 PROTAC on tumor growth. C is the statistical analysis results of AML tumor burden in mice in the control group, reverse peptide and ZMYND8 PROTAC group. D is the survival of mice in the control group, reverse peptide and ZMYND8 PROTAC group. DETAILED DESCRIPTION

[0031] The following describes the implementation of the present invention by means of specific embodiments. Those skilled in the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification.

[0032] The present invention provides a PROTAC polypeptide targeting ZMYND8, and the amino acid sequence of the PROTAC polypeptide is shown in SEQ ID NO: 1: QYDANCKKEDTTYITYGGG SGGGTSFEQFWAWLWP.

[0033] The present invention has no special restrictions on the source of the polypeptide, and any polypeptide source known in the art can be used. In the embodiment of the present invention, the polypeptide is synthesized using a polypeptide solid phase synthesis method. The present invention has no special restrictions on the polypeptide solid phase synthesis method, and any polypeptide synthesis method known in the art can be used, such as Fmoc polypeptide synthesis. Fmoc protected amino acids were purchased from Jier Biochemical, and HBTU and HIBT condensing agents were from Suzhou Haofan Biotechnology.

[0034] In the present invention, an isothermal calorimetric titration experiment is used to detect the binding ability of PROTAC polypeptide to ZMYND8 protein, and the binding constant of PROTAC polypeptide to ZMYND8 protein is preferably 324nM. The polypeptide binds to ZMYND8 protein and MDM2 protein, induces MDM2 protein to ubiquitinate ZMYND8, and achieves the result of mediating ZMYND8 degradation in acute myeloid leukemia. Figure 1 E, F. Crystal structure of ZMYND8 homodimer Figure 1 As shown in A.

[0035] In the present invention, PROTAC peptides were delivered into acute myeloid leukemia cells using nano-selenium, and cell proliferation was found to be inhibited. The IC of peptide drugs for MOLM-13 acute myeloid leukemia cells for 24 hours 50 The IC value was 0.44 μM for 48 hours. 50 The IC value for THP-1 acute myeloid leukemia cells for 24 hours is 0.18 μM. 50 The IC value was 0.81 μM for 48 hours. 50 The IC value for MV4-11 acute myeloid leukemia for 24 hours is 0.33 μM. 50 The IC value is 0.51 μM for 48 hours. 50 The IC value for M07e acute myeloid leukemia at 24 hours is 0.21 μM. 50 IC of 0.20 μM for 48 hours 50 The IC value for NB4 acute myeloid leukemia for 24 hours is 0.09 μM. 50 IC of 0.28 μM for 48 hours 50 It is 0.14μM.

[0036] In view of the function of PROTAC polypeptides in targeting and inhibiting the proliferation of acute myeloid leukemia cells, the present invention provides the use of PROTAC polypeptides in the preparation of drugs for preventing and / or treating acute myeloid leukemia.

[0037] In the present invention, the acute myeloid leukemia preferably includes one or more of the following acute myeloid leukemia cells: MOLM-13, THP-1, MV4-11, M07e or NB4.

[0038] In view of the function of PROTAC polypeptide to degrade intracellular ZMYND8 protein, the present invention provides the use of PROTAC polypeptide targeting ZMYND8 protein in the preparation of an agent for degrading ZMYND8 protein.

[0039] The present invention provides a drug for preventing and / or treating acute myeloid leukemia, comprising a PROTAC polypeptide and a delivery system.

[0040] The present invention does not impose any special restrictions on the type of delivery system, and a delivery system well known in the art can be used, such as nanogold, liposomes, nanoselenium or other nano delivery systems well known in the art. In the embodiments of the present invention, nanoselenium is used as a delivery system as an example to illustrate the preparation method and efficacy of the drug. The present invention does not impose any special restrictions on the preparation method of nanoselenium-polypeptide drugs, and a method of nanoselenium coupling protein well known in the art can be used. The drug has been experimentally confirmed to be non-toxic at the cellular level and animal level, and has a high safety.

[0041] The PROTAC polypeptide targeting the ZMYND8 protein provided by the present invention, its application, and the effect of preventing and treating acute myeloid leukemia are described in detail below in conjunction with the examples, but they should not be construed as limiting the scope of protection of the present invention.

[0042] Description of experimental materials

[0043] The experimental materials are divided into the synthesis part: Fmoc amino acid was purchased from Shanghai Jier Biochemical, DIEA, HOBT, and HBTU were purchased from Sigma-Aldrich (a subsidiary of Merck Life Sciences). The nano-selenium preparation part is: sodium selenite, chitosan, and vitamin C were purchased from Aladdin Reagents.

[0044] Noun Description

[0045] Se stands for single nanoselenium delivery system;

[0046] ZMYND8 PROTAC@NanoSe represents the finished product that is coupled with peptide drugs and nano-selenium delivery system;

[0047] Reverse peptide represents the finished product coupled with peptide negative control and nano-selenium delivery system;

[0048] Control represents blank control;

[0049] Vinculin represents focal adhesion protein and was used as an internal control in western blotting;

[0050] Chx stands for Cycloheximide, a protein production inhibitor.

[0051] Example 1

[0052] Protein-assisted design was used to obtain PROTAC peptides targeting ZMYND8 protein, such as Figure 1 As shown in B and C.

[0053] Peptide drugs were synthesized according to the amino acid sequence using the peptide solid phase synthesis method. The synthesis method was general Fmoc peptide synthesis. Fmoc protected amino acids were purchased from Jier Biochemical, and HBTU and HIBT condensation agents were from Suzhou Haofan Biotechnology. The synthesis method is as follows:

[0054] 1) Deprotection: Fmoc-protected columns and monomers must be treated with an alkaline solvent (piperidine) to remove the amino protecting group.

[0055] 2) Activation and cross-linking: The carboxyl group of the next amino acid is activated by an activator. The activated monomer reacts with the free amino group to cross-link and form a peptide bond. In this step, a large amount of superconcentrated reagents are used to drive the reaction to completion. Cycle: These two steps are repeated until the synthesis is complete.

[0056] 3) Elution and deprotection: The polypeptide is eluted from the column and its protecting groups are eluted and deprotected by a deprotecting agent (TFA) to obtain a crude product.

[0057] The amino acid sequence of the PROTAC polypeptide is QYDANCKKEDTTYITYGGG SGGGTSFEQFWAWLWP (SEQ ID NO: 1).

[0058] The HPLC characterization results of PROTAC peptides are as follows Figure 1 As shown in D.

[0059] Example 2

[0060] Preparation of ZMYND8 PROTAC@NanoSe drug

[0061] The coupling method is as follows: 1 mg of the peptide is dissolved in 1 ml of pure water, 200 μl of 50 mM sodium selenite solution and 600 μl of 0.5% chitosan solution are added, the solution is shaken and mixed until the solution is clear, and the solution is placed in a water bath preheated at 50°C for 1 min. Then, 1.6 ml of 50 mM vitamin C solution is added to the preheated mixed solution, and the mixture is placed in a 50°C water bath for 20 min after mixing, and then taken out to obtain nano-selenium drug-loaded particles, which are cooled to room temperature to obtain the peptide drug ZMYND8 PROTAC@NanoSe coupled with nano-selenium.

[0062] Example 3

[0063] Cell-level experiments of ZMYND8 PROTAC@NanoSe drugs

[0064] 1. Cell culture

[0065] MOLM-13, THP-1, MV4-11, M07E, NB4 cells were cultured in a complete medium of 90% RPMI 1640 + 10% FBS. The cells were cultured in a constant temperature incubator at 37°C and 5% CO2 with saturated humidity. The cell culture density was maintained at 4×10 5 ~2×10 6 / ml.

[0066] 2. Experiment on the ability of drugs to inhibit cancer cell proliferation

[0067] The Cell Counting Kit-8 detection method is used to analyze the ability of drugs to inhibit the proliferation of cancer cells.

[0068] The basic principle of the CCK8 cell activity assay is that the reagent contains a compound WST-8 (its chemical name is 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfonic acid benzene)-2H-tetrazole monosodium salt). In the cell, WST-8, with the assistance of a specific coupling reagent, will be reduced by dehydrogenases in the mitochondria to produce a yellow water-soluble formazan product, the concentration of which is proportional to the viability of the cell. Specifically, the more active cells there are, the more formazan products are generated, and the darker the color of the test solution. Conversely, if there are fewer live cells, the formazan products produced are reduced, and the color of the solution is correspondingly lighter. By measuring the color depth of the solution, the activity level of the cell can be indirectly reflected. This method is not only simple to operate, but also highly sensitive, and is suitable for evaluating the activity of various types of cells.

[0069] When using CCK8 to detect cell activity, the specific experimental steps are as follows: First, inoculate cells, count AML cells and dilute them into 5×10 5 / ml, and inoculated into a 96-well plate at a volume of 90μl per well. Set up a drug group, a control group (no drug) and a background blank control group (complete culture medium without cells), and set up 3 replicate wells for each concentration. Next is drug treatment, add different concentration gradients of drugs to the drug group, and continue culturing for 24h or 48h. After the drug treatment, use CCK8 to detect cell viability, add 10μl of CCK8 reagent to each well, gently tap the 96-well plate to mix, and then place it in a constant temperature incubator and culture it at 37°C for 2h. After incubation, use a full-wavelength enzyme-linked immunosorbent detector to measure the absorbance of each well at wavelengths of 450nm and 690nm. After obtaining the absorbance reading, calculate the OD 450 With OD 690 Finally, the cell activity index is evaluated according to a specific calculation formula.

[0070] After drug treatment, the detection and calculation showed that the finished product representing the conjugation of peptide drugs and nano-selenium delivery system had an inhibitory effect on the proliferation of acute myeloid leukemia cells.

[0071] Results Figure 2 A. ZMYND8 PROTAC@NanoSe drug showed dose-dependent growth inhibition in MOLM-13, THP-1, MV4-11, M07e and NB4 cells, while naked nanoselenium particles had no effect on cancer cells. The 24-hour half-maximal inhibitory concentration (IC 50 ) values ​​are IC 50 They are 0.44μM, 0.81μM, 0.51μM, and 0.20μM.

[0072] 3. In order to study the degradation ability of ZMYND8 PROTAC@NanoSe drug on ZMYND8 protein, protein immunoblotting (western blotting) was used to analyze ZMYND8. The specific experimental process is as follows:

[0073] First, AML cells were cultured at 5 × 10 5 / ml density was inoculated into a 12-well plate, and then different concentrations of drugs were added to the cells, and a control group without drugs was set up, and the cells were cultured in an incubator at 37℃ and 5% CO2 for 24h. The cells in each well were collected by centrifugation at 300g for 5min, washed 3 times with PBS, and the supernatant was discarded by centrifugation. 45μl of RIPA lysis buffer containing protease inhibitor PMSF was added to each cell sample, and the cells were vortexed and mixed, and then placed on ice for 30min. After the cells were completely lysed, centrifuged at 12000rpm and 4℃ for 15min, and then 5μl of lysis supernatant was taken from each sample to quantify the protein sample using the BCA quantitative kit. Loading buffer was added to the remaining lysis supernatant, mixed, and placed in a metal bath at 100℃ for 10min to completely denature the protein sample. After the protein sample was prepared, the sample and pre-stained standard protein marker were added to the loading well of the SDS-PAGE gel, and the sample volume of each well was filled up according to the quantitative results, and then the protein was separated by electrophoresis. The proteins on the SDS-PAGE gel were transferred to the PVDF membrane using the rapid semi-dry transfer method. The membrane was then blocked with TBST containing 1% BSA at room temperature for 1 hour. After blocking, the membrane was incubated with the specific primary antibody solution on a shaker at 4°C overnight. The next day, the membrane incubated overnight was washed 3 times with TBST solution, and then the secondary antibody solution of the corresponding species was prepared with TBST solution containing 1% BSA. The prepared secondary antibody solution was poured into the membrane incubated with the primary antibody of the corresponding species and incubated on a horizontal shaker at room temperature for 1 hour. After the secondary antibody incubation was completed, the membrane was washed 3 times with TBST. Finally, the target protein was detected by chemiluminescence using ECL luminescent solution. The obtained protein bands were analyzed in grayscale using image J software, and statistical analysis was performed in GraphPad 8.0.

[0074] ZMYND8 PROTAC@NanoSe drug showed dose-dependent ( Figure 2 B~E) induces the degradation of ZMYND8 protein in two ways: expression and time-dependent.

[0075] 4. ZMYND8 PROTAC@NanoSe drug can induce apoptosis of primary cells in bone marrow samples of AML patients

[0076] In order to verify the efficacy of ZMYND8 PROTAC@NanoSe in AML patient samples, AML patient bone marrow samples were collected. After obtaining the bone marrow samples of AML patients, the bone marrow samples were first transferred to a 15ml centrifuge tube in an ultra-clean workbench, and PBS and erythrocyte sedimentation fluid were added in a ratio of 1:1:1. The mixture was gently blown and mixed with a pipette and allowed to stand at room temperature for 25 minutes. After the sedimentation was completed, the upper liquid was aspirated into a new centrifuge tube and the precipitate was discarded. The upper liquid was centrifuged at a centrifugal force of 1000 rpm for 5 minutes. After the centrifugation was completed, the supernatant in the tube was removed and discarded, and the cell sediment at the bottom of the tube was resuspended and evenly mixed with phosphate buffered saline (PBS). Next, three times the volume of erythrocyte lysis solution was added to the centrifuge tube, gently shaken, and the tube was placed at room temperature for 15 minutes to further lyse the remaining erythrocytes. After the erythrocyte lysis was completed, centrifuged at 1000rpm, the supernatant was discarded, and the cell precipitate was obtained. If there were still erythrocytes remaining at this time, the lysis could be repeated once. Finally, the cell pellet after lysing red blood cells was washed three times with PBS, and the cells were resuspended in RPMI 1640 medium enriched with 10% fetal bovine serum (FBS), and then transferred to cell culture flasks. Then, these culture flasks were placed in an incubator at 37°C and 5% CO2 for culture.

[0077] After obtaining bone marrow samples from AML patients, red blood cells were removed by erythrocyte sedimentation and lysis, and the cells were resuspended in RPMI 1640 medium containing 10% FBS and cultured at 5×10 5 / ml density was inoculated into 24-well plates, and an empty nano-selenium (Se) negative control group was set up, which was equivalent to 1.0μM concentration of ZMYND8 PROTAC@NanoSe. The drug group was set up with a concentration gradient of 0.25μM, 0.5μM, and 1.0μM, and was added to the bone marrow cells of AML patients respectively. After 24h of drug treatment, apoptosis was detected using the PI-AnnexinV apoptosis detection kit.

[0078] like Figure 3 As shown: Empty nanoselenium (Se) does not induce apoptosis of patient bone marrow cells, while different concentrations of ZMYND8PROTAC drugs can induce apoptosis of primary bone marrow cells.

[0079] Example 4

[0080] Verification of the inhibitory effect of ZMYND8 PROTAC@NanoSe drug on tumor growth at the animal level

[0081] In order to evaluate the therapeutic effect of ZMYND8 PROTAC@NanoSe drug in vivo, an acute myeloid leukemia mouse model was established. 5-week-old female NSG mice were used. These mice were raised in an SPF-level animal laboratory and kept in a 12-h day and night cycle environment. After 1 week of feeding, MOLM-13-Luc cells were injected through the tail vein, and each mouse received approximately 1×10 4 cells. Seven days after the successful injection of AML cells, D-luciferin potassium salt was used as the substrate of luciferase to detect the AML tumor burden of the model mice. Use sterile DPBS buffer to dissolve and prepare a 15 mg / ml substrate storage solution and mix well. Filter the stock solution with a 0.2 μm filter to sterilize. When imaging mice, inject 15 mg / ml D-luciferin potassium salt into the mouse by intraperitoneal injection at a dose of 200 μl / mouse. After reacting for about 10 minutes, anesthetize the mouse with isoflurane inhalation anesthesia. Put the anesthetized mouse in The bioluminescence intensity was detected in the LuminaXRMS Series III small animal imager, and the AML tumor burden was assessed based on the bioluminescence intensity of each mouse.

[0082] The correct structure of the polypeptide determines its function, and only polypeptides with the correct sequence can play their role. In order to better verify the effect of the ZMYND8 PROTAC polypeptide on AML cells, the present invention synthesized a reverse peptide (reverse peptide) that is exactly opposite to the sequence of the ZMYND8 PROTAC polypeptide, and its amino acid composition is exactly the same as that of the ZMYND8 PROTAC polypeptide. Therefore, the reverse peptide can be used as an optimal negative control for the ZMYND8 PROTAC polypeptide. The present invention uses the same preparation method to prepare nano-selenium particles loaded with reverse peptides, which are named Reverse Peptide@NanoSe.

[0083] The mice with successful modeling were randomly divided into three groups: control group (Vehicle), reverse peptide group (ReversePeptide@NanoSe, labeled as Reverse Peptide) and drug group (ZMYND8 PROTAC@NanoSe, labeled as ZMYND8 PROTAC), with 5 mice in each group. The drug dose of reverse peptide and ZMYND8 PROTAC peptide was 5 mg / kg (mouse body weight), and the control group was given an equal amount of normal saline. The administration method was intraperitoneal injection, once every other day, for 14 consecutive days. During the administration period, imaging was performed once a week to evaluate tumor burden and mouse survival.

[0084] like Figure 4As shown in A to D, the control group and reverse peptide had no therapeutic effect on tumor growth, while ZMYND8PROTAC@NanoSe drug showed high efficacy in MOLM-13 xenograft model and prolonged the survival of AML mice.

[0085] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A PROTAC polypeptide targeting ZMYND8 protein, characterized in that The amino acid sequence of the PROTAC polypeptide is shown in SEQ ID NO:

1.

2. Use of the PROTAC polypeptide according to claim 1 in preparing a product for degrading ZMYND8 protein.

3. Use of the PROTAC polypeptide according to claim 1 in the preparation of a medicament for preventing and / or treating leukemia.

4. The use according to claim 3, characterized in that: The PROTAC polypeptide is used to prepare a drug for inhibiting the proliferation of leukemia cells.

5. The application according to claim 4, characterized in that: The leukemia cells are MOLM-13, THP-1, MV4-11, M07e, NB4 or primary AML cells from bone marrow samples of patients with acute myeloid leukemia.

6. A drug for preventing and / or treating leukemia, characterized in that: It comprises the PROTAC polypeptide according to claim 1 and a pharmaceutically acceptable excipient or carrier.

7. The drug according to claim 6, characterized in that: The carrier is nano-selenium, nano-gold or liposome.

8. The drug according to claim 7, characterized in that The carrier is nano-selenium.

9. The drug according to claim 8, characterized in that: The drug is prepared according to the following steps: The PROTAC polypeptide, the aqueous solution of selenium salt and the chitosan solution are mixed and then placed in a water bath, and vitamin C is added and reacted to obtain the product.

10. The drug according to claim 9, characterized in that The molar mass ratio of the PROTAC polypeptide, selenium salt, and vitamin C is 1:8-12:70-90; The mass concentration of the chitosan solution is 0.3-0.8%, and the dosage ratio of the chitosan solution to the PROTAC peptide is 150 μL: 1 mg; After mixing the PROTAC polypeptide, chitosan solution and aqueous solution of selenium salt, vitamin C is added at 45-55° C., and the reaction is continued for 15-25 minutes. After stabilization at room temperature, the drug is obtained.